These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
85 related items for PubMed ID: 8165609
1. Antithrombotic activity of Bay u3405, a thromboxane A2-antagonist, in patients with Dacron aortic grafts: a random controlled clinical trial. Pieters H, Roodt JP, Badenhorst PN, van Wyk V, Schall R, Lötter MG, Hundt HK, Nel CJ. Thromb Haemost; 1993 Dec 20; 70(6):903-8. PubMed ID: 8165609 [Abstract] [Full Text] [Related]
2. In vivo inhibition of acute platelet-dependent thrombosis in a baboon model by Bay U3405, a thromboxane A2-receptor antagonist. Kotzé HF, Lamprecht S, Badenhorst PN, van Wyk V, Roodt JP, Alexander K. Thromb Haemost; 1993 Oct 18; 70(4):672-5. PubMed ID: 8115994 [Abstract] [Full Text] [Related]
3. Ex vivo inhibition of platelet aggregation in patients with severe limb arteriopathy treated with BAY U3405, a specific TX A2 receptor antagonist. Bellucci S, Kedra W, Groussin H, Jaillet N, Molho-Sabatier P, Andreassian B, Tobelem G. Thromb Haemost; 1994 Nov 18; 72(5):659-62. PubMed ID: 7900069 [Abstract] [Full Text] [Related]
4. A specific thromboxane receptor blocking drug, AH23848, reduces platelet deposition on vascular grafts in man. Lane IF, Lumley P, Michael MF, Peters AM, McCollum CN. Thromb Haemost; 1990 Nov 30; 64(3):369-73. PubMed ID: 2151407 [Abstract] [Full Text] [Related]
7. The thrombogenicity of Dacron arterial grafts and its modification by platelet inhibitory drugs. Kester RC. Ann R Coll Surg Engl; 1984 Jul 30; 66(4):241-6. PubMed ID: 6234841 [Abstract] [Full Text] [Related]